Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. Pommier, R. F., Fisher, G. A., Wolin, E. M., Kunz, P. L., Liyanage, N., Lowenthal, S., Mirakhur, B., Shaheen, M. F., Vinik, A. AMER SOC CLINICAL ONCOLOGY. 2017
View details for Web of Science ID 000443281700368